MP30-08 ANTIBODY RESPONSES TO BNT162B2 mRNA COVID-19 VACCINE IN HEALTHCARE WORKERS AND PATIENTS WITH UROLOGICAL DISEASES IN JAPAN

Abstract

You have accessJournal of UrologyCME1 May 2022MP30-08 ANTIBODY RESPONSES TO BNT162B2 mRNA COVID-19 VACCINE IN HEALTHCARE WORKERS AND PATIENTS WITH UROLOGICAL DISEASES IN JAPAN Shingo Hatakeyama, Tohru Yoneyama, Tomoko Hamaya, Kyo Togashi, Takuma Narita, Naoki Fujita, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, and Chikara Ohyama Shingo HatakeyamaShingo Hatakeyama More articles by this author , Tohru YoneyamaTohru Yoneyama More articles by this author , Tomoko HamayaTomoko Hamaya More articles by this author , Kyo TogashiKyo Togashi More articles by this author , Takuma NaritaTakuma Narita More articles by this author , Naoki FujitaNaoki Fujita More articles by this author , Hayato YamamotoHayato Yamamoto More articles by this author , Takahiro YoneyamaTakahiro Yoneyama More articles by this author , Yasuhiro HashimotoYasuhiro Hashimoto More articles by this author , and Chikara OhyamaChikara Ohyama More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002573.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Patients with cancer and solid organ transplantation are at risk for immune dysregulation related to underlying malignant disease and immunomodulatory therapy. There is a great concern for protective immune response to SARS-CoV-2vaccination in those patients. We aimed to evaluate rates of anti-spike antibody response to a BNT162b2 vaccine in patients with urological cancers, kidney transplantation, and healthy controls in a single tertiary referral hospital in Japan. METHODS: This retrospective study included 280 adult patients with urological cancers, 93 adult patients with kidney transplantation, and 60 healthcare workers (controls) who received the second dose of the BNT162b2 vaccine at least 7 days before evaluation. The study was conducted between June 21, 2021, and November 1, 2021, at Hirosaki University Hospital (Hirosaki, Japan). Blood samples were cross-sectionally obtained from the study participants. Serum samples were analyzed and the titers of the IgG antibodies against the SARS-CoV-2 spike receptor-binding domain were determined using the Elecsys Anti-SARS-CoV-2 S RUO (Roche-diagnostics). Seropositivity was defined as >15 Unit/mL (sufficient for the presence of neutralizing antibodies). The primary outcome was the rate of seropositivity (>15 Unit/mL). Secondary outcomes included the decay of IgG titers over time and identifying factors that were associated with seropositivity using multivariable logistic regression analyses. RESULTS: The analysis included 195 patients with prostate cancer (PC) (median age 75 years), 57 patients with urothelial cancer (UC) (median age 73 years), 28 patients with renal cell carcinoma (RCC) (median age 72 years), 93 patients with kidney transplantation (KT) (median age 55 years), and 60 controls (median age 36 years). Of 433, we observed seropositive in 341 (79%) participants. The rate of seropositive for SARS-CoV-2 anti-spike IgG antibodies after the second vaccine in the patients with KT, PC, UC, RCC, and Ctrl were 23%, 94%, 88%, 96%, and 100%, respectively. The antibody titers were elevated 1 week after the second dose of the BNT162b2 vaccine. Multivariable analysis showed that age (HR 0.95, P=0.002), metastatic disease (HR0.25, P=0.021), and immunosuppression (HR 0.003, P<0.01) were significantly associated with seropositivity. A minimum dose of steroids or immune-checkpoint inhibitors was not significantly associated with seropositivity. CONCLUSIONS: We observed a remarkably lower rate of seropositive in KT patients, while approximately 90% of patients with cancer exhibited adequate antibody response to the BNT162b2 vaccine. Further research is required for the durability and protective activity of lower titers for breakthrough infections. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e481 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Shingo Hatakeyama More articles by this author Tohru Yoneyama More articles by this author Tomoko Hamaya More articles by this author Kyo Togashi More articles by this author Takuma Narita More articles by this author Naoki Fujita More articles by this author Hayato Yamamoto More articles by this author Takahiro Yoneyama More articles by this author Yasuhiro Hashimoto More articles by this author Chikara Ohyama More articles by this author Expand All Advertisement PDF DownloadLoading ...